Umekubo John I MD is categorized under Internal Medicine Practitioners in San Francisco, CA and active since 1980.
Umekubo John I MD was established in 1980, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Internal Medicine Practitioners business, which does work in the B2C market, and is classified as a Internal Medicine Practitioners, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact John Umekubo at the company’s single location by writing to 1674 Post St, San Francisco, California CA 94115 or by phoning (415) 931-5182. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Umekubo John I MD |
| Contact Person: | John Umekubo |
| Address: | 1674 Post St, San Francisco, California 94115 |
| Phone Number: | (415) 931-5182 |
| Website Address: | sfjapantown.org |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1980 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Practitioners |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Umekubo John I MD was started in 1980 to provide professional Internal Medicine Practitioners under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact John Umekubo for inquiries that concern Umekubo John I MD by calling the company number (415) 931-5182, as your correspondence is most welcome. Additionally, the physical location of the single location of Umekubo John I MD can be found at the coordinates 37.785758,-122.429422 as well as the street address 1674 Post St in San Francisco, California 94115.
For its online presence, you may visit Umekubo John I MD’s website at sfjapantown.org and engage with its social media outlets through on Twitter and on Facebook.